Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Employment agrmnt
Quarterly results
Appointed director
Biofrontera Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
10/13/2023 8-K Quarterly results
10/10/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Biofrontera Inc. Receives FDA Approval for New Formulation of Ameluz"
10/04/2023 S-1 Form S-1 - General form for registration of securities under the Securities Act of 1933:
10/04/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Biofrontera Inc. Announces Preliminary Third Quarter Revenues"
10/03/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Independent Registered Public Accounting Firm’ s Consent",
"5 $ 20 $ 82 6. Investment, Related Party",
"For the Year Ended December 31,"
08/11/2023 8-K Quarterly results
Docs: "Biofrontera Inc. Reports Second Quarter 2023 Financial Results and Provides a Business Update"
08/11/2023 10-Q Quarterly Report for the period ended June 30, 2023
07/13/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Biofrontera Inc. Announces Preliminary Second Quarter Revenues are Up 26% to 31%"
07/12/2023 8-K Quarterly results
07/03/2023 8-K Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...
Docs: "CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF OF BIOFRONTERA INC.",
"Biofrontera Inc. Announces 1-for-20 Reverse Stock Split"
06/02/2023 8-K Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits  Interactive Data
06/01/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Biofrontera Inc. Begins Development of a Portable Photodynamic Therapy Lamp for Use with Ameluz-PDT"
05/26/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Departure of Directors o...
Docs: "Dear Fred, Dan and Board Members:"
05/12/2023 8-K Quarterly results
Docs: "Biofrontera Inc. Reports First Quarter 2023 Financial Results and Provides a Business Update",
"Biofrontera Inc. Announces Resignation of CEO"
04/28/2023 8-A12B/A Form 8-A12B/A - Registration of securities [Section 12(b)]: [Amend]
04/28/2023 8-K Entry into a Material Definitive Agreement, Material Modifications to Rights of Security Holders, Financial Statements and Ex...
Docs: "AMENDMENT NO. 1 TO STOCKHOLDER RIGHTS AGREEMENT"
04/21/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/17/2023 8-K Quarterly results
03/13/2023 10-K Annual Report for the period ended December 31, 2022
03/08/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Biofrontera Inc. Reports Fourth Quarter and Record Full-year 2022 Financial Results"
03/02/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
01/09/2023 8-K Quarterly results
12/16/2022 8-K Appointed a new director
Docs: "Option Price"
12/08/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
11/29/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
11/21/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
11/15/2022 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
11/15/2022 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
11/08/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Biofrontera Inc. Fully Exercises Recently Acquired Options to Purchase Shares of Biofrontera AG"
11/08/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
11/08/2022 EFFECT Form EFFECT - Notice of Effectiveness:
11/04/2022 D Form D - Notice of Exempt Offering of Securities:
11/04/2022 SC 13G Abshagen Consulting GmbH reports a 11.8% stake in Biofrontera Inc.
11/02/2022 S-1 Form S-1 - General form for registration of securities under the Securities Act of 1933:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy